PMID- 26137152
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 1792-1074 (Print)
IS  - 1792-1082 (Electronic)
IS  - 1792-1074 (Linking)
VI  - 9
IP  - 6
DP  - 2015 Jun
TI  - Glucose transporter 3 performs a critical role in mTOR-mediated oncogenic 
      glycolysis and tumorigenesis.
PG  - 2809-2814
AB  - The present study aimed to examine the relationship between mammalian target of 
      rapamycin (mTOR) and glucose transporter 3 (Glut3) in the process of 
      mTOR-mediated oncogenic glycolysis and tumorigenesis. Western blot analysis and 
      quantitative polymerase chain reaction were used to compare the expression of 
      Glut3 in mouse embryonic fibroblasts (MEFs) null for tuberous sclerosis complex 2 
      (Tsc2(-/-)) and control Tsc2(+/+) MEFs. In addition, the glycolytic rate was 
      tested following siRNA-mediated knockdown of Glut3 in Tsc2(-/-) cells. To 
      determine whether Glut3 depletion affects the ability of cells to form tumors in 
      vivo. Tsc2(-/-) MEFs infected shGlut3 and shControl were injected into nude mice 
      subcutaneously. The present study demonstrated that the expression of Glut3 is 
      controlled by mTOR in Tsc2(-/-) cells and that downregulation of Glut3 reduced 
      the glycolytic rate in Tsc2(-/-) cells. cells. Further studies in nude mice 
      demonstrated that reduced Glut3 expression levels reduced the tumorigenetic 
      effect in cells with hyperactive mTOR complex 1 (mTORC1). The present study 
      indicates for the first time that Glut3 is a downstream target of mTORC1 and that 
      Glut3 is critical in mTORC1-associated tumorigenesis. Therefore, Glut3 is a 
      potential target for the treatment of diseases associated with dysregulated 
      mTORC1 signaling.
FAU - Zhang, Yanbin
AU  - Zhang Y
AD  - Department of Urology, The First Affiliated Hospital of Anhui Medical University, 
      Hefei, Anhui 230032, P.R. China ; Department of Urology, Hefei Hospital 
      Affiliated to Anhui Medical University and The Second People's Hospital of Hefei, 
      Hefei, Anhui 230011, P.R. China.
FAU - Wei, Can
AU  - Wei C
AD  - Department of Urology, The First Affiliated Hospital of Anhui Medical University, 
      Hefei, Anhui 230032, P.R. China ; Department of Urology, Hefei Hospital 
      Affiliated to Anhui Medical University and The Second People's Hospital of Hefei, 
      Hefei, Anhui 230011, P.R. China.
FAU - Xi, Junhua
AU  - Xi J
AD  - Department of Urology, The First Affiliated Hospital of Anhui Medical University, 
      Hefei, Anhui 230032, P.R. China.
FAU - Tang, Zhiguo
AU  - Tang Z
AD  - Department of Urology, The First Affiliated Hospital of Anhui Medical University, 
      Hefei, Anhui 230032, P.R. China.
FAU - Liang, Chaozhao
AU  - Liang C
AD  - Department of Urology, The First Affiliated Hospital of Anhui Medical University, 
      Hefei, Anhui 230032, P.R. China ; Department of Urology, Hefei Hospital 
      Affiliated to Anhui Medical University and The Second People's Hospital of Hefei, 
      Hefei, Anhui 230011, P.R. China.
LA  - eng
PT  - Journal Article
PT  - Retracted Publication
DEP - 20150326
PL  - Greece
TA  - Oncol Lett
JT  - Oncology letters
JID - 101531236
RIN - Oncol Lett. 2015 Nov;10 (5):3332. PMID: 26722335
PMC - PMC4473674
OTO - NOTNLM
OT  - Glut3
OT  - glycolysis
OT  - mTOR
OT  - tumorigenesis
EDAT- 2015/07/03 06:00
MHDA- 2015/07/03 06:01
PMCR- 2015/03/26
CRDT- 2015/07/03 06:00
PHST- 2014/07/13 00:00 [received]
PHST- 2015/03/02 00:00 [accepted]
PHST- 2015/07/03 06:00 [entrez]
PHST- 2015/07/03 06:00 [pubmed]
PHST- 2015/07/03 06:01 [medline]
PHST- 2015/03/26 00:00 [pmc-release]
AID - OL-0-0-3075 [pii]
AID - 10.3892/ol.2015.3075 [doi]
PST - ppublish
SO  - Oncol Lett. 2015 Jun;9(6):2809-2814. doi: 10.3892/ol.2015.3075. Epub 2015 Mar 26.